<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916757</url>
  </required_header>
  <id_info>
    <org_study_id>Imm008</org_study_id>
    <nct_id>NCT03916757</nct_id>
  </id_info>
  <brief_title>V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer</brief_title>
  <acronym>GBM</acronym>
  <official_title>Open-label Phase II Trial of the Safety and Efficacy of V-Boost in Patients With Refractory Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase II study to determine the safety and efficacy of V-Boost in treating a type of
      brain cancer called Glioblastoma Multiforme (GBM). V-Boost is an immunotherapy in which the
      patient's immune system will be modulated to eliminate tumor cells. V-Boost is made as an
      oral tablet which contains specially formulated hydrolyzed GBM antigens along with
      alloantigens. Patients are either newly diagnosed or with recurrent form of GBM who may have
      been subjected to surgery and/or chemo- or radiation therapy that ended up unsuccessful. The
      goal is to eradicate GBM tumor cells through daily oral administration of one pill of V-Boost
      immunotherapeutic vaccine, which so far has not shown any adverse reaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed Phase II trial is an-open label study of the safety and efficacy of V-Boost in
      newly diagnosed or treatment-refractory patients with glioblastoma multiforme (GBM) following
      unsuccesfull resection and/or chemoradiation. The Phase I clinical tria,l carried out in a
      small, open-label study, demonstrated safety and promising efficacy. The purpose of this
      study is to gain additional information from a larger clinical trial aimed to recruit at
      least 20 patients with GBM. Patients may be newly diagnosed with GBM or are those who have
      been subjected to resection and/or chemotherapy or radiation, but without success. Patients
      need to have imaging records and health assessment prior to study enrollment. Those on
      chemotherapy or radiation can be in washout period or may receive immunotherapy concurrently.
      Patients will be administered daily dose of V-Boost oral tablet for at least one month and
      additional dosing can be envisaged depending on outcome of first month. The primary objective
      is to evaluate the effect on tumor size and progression free survival (PFS) in comparison to
      patients on standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients who passed eligibility requirement will receive daily dose of V-Boost</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is open label study, no masking is required</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on tumor size</measure>
    <time_frame>3 months</time_frame>
    <description>Imaging of brain at 3-month time post-therapy and comparison to baseline records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on progression-free survival</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of patients status on progression free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Glioma of Brain</condition>
  <arm_group>
    <arm_group_label>V-Boost recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this open label study all eligible participants will receive daily tablet of V-Boost</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V-Boost</intervention_name>
    <description>Open label setting</description>
    <arm_group_label>V-Boost recipients</arm_group_label>
    <other_name>V-Boost Immunitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of GBM

          -  â‰¥ 5 years of age

          -  Consent from parents or legal guardian if under-aged

        Exclusion Criteria:

          -  Severe pulmonary, cardiac or other systemic disease

          -  Presence of an acute infection requiring active treatment with antibiotics/antivirals

          -  Receiving corticosteroids (e.g., dexamethasone) during study duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldar Bourinbayar, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunitor LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldar Bourinbaiar, MD/PhD</last_name>
    <phone>+97695130306</phone>
    <email>immunitor@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Galyna Kutsyna, MD</last_name>
    <phone>+97695130306</phone>
    <email>kutsynagalyna@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Immunitor LLC</name>
      <address>
        <city>Ulaanbaatar</city>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldar Bourinbaiar, MD</last_name>
      <phone>97695130306</phone>
      <email>aldar@immunitor.com</email>
    </contact>
    <contact_backup>
      <last_name>Aldar Bourinbayar, MD</last_name>
      <phone>+97695130306</phone>
      <phone_ext>Bourinbayar</phone_ext>
      <email>immunitor@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aldar Bourinbaiar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28443252</url>
    <description>link to similar study</description>
  </link>
  <reference>
    <citation>Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, Borisova V, Bain AI, Jirathitikal V, Bourinbaiar AS. Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcinoma. 2017 Apr 12;4:59-69. doi: 10.2147/JHC.S122507. eCollection 2017.</citation>
    <PMID>28443252</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

